After failing to buy Illumina in 2012 and deciding to close its 454 Life Sciences sequencing unit last year, Roche has been looking for technologies to strengthen its diagnostic business.
Having seen off Roche's 454 Life Sciences and established a big lead over its remaining rivals, Illumina now faces a new challenger for the DNA sequencing market.
Enzymatics is expanding its offerings in the DNA sequencing market with the buyout of startup ArcherDx, which provides kits and software for evaluating cancer treatment. Add up the cash, Enzymatics equity and potential milestone fees in the deal, and the buyout could be worth up to $50 million.
Roche has unveiled a software update for improving DNA sequencing studies, for which advances in information technology have become crucial to improving accuracy and speed of 'omics data analysis.
For most people in the Western world, the mention of tuberculosis is likely to conjure up images of the Victorians. In richer countries, tuberculosis is, for the most part, a thing of the past.
University of Wisconsin researchers have undertaken a genomic study involving patients with cystic fibrosis, aiming to uncover data that explain variation in symptoms among those afflicted with the genetic lung disease. And researchers believe that bioinformatics and other new resources give them an "edge" in the fight to improve treatments, according to the university's release.
Roche has developed web-based software that enables the company's customers to quickly design sequence libraries and improve the process of target enrichment custom design for next-generation sequencing.
As genomic data swells beyond expectations, researchers face a dilemma over how to secure the information on people's DNA without stymying progress in the genomics revolution. In an opinion column in Nature, University of California, Berkeley Professor Steven Brenner tackles the issue and lays out a set of potential solutions.
Roche Diagnostics has kicked off commercialization for a new bead-based DNA reagent kit, a sequencing tool the company hopes will boost revenue in its flagging research-use technology business.
Sanofi research czar Elias Zerhouni has pushed for the company to delve deeply into the study of diseases before leaping into drug development. Now the French drug giant plans to collaborate with the software company NextBio to infuse patients' genomic and other data into its work on treatments for such diseases as cancer and diabetes.